AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (fr)
EP (1) EP0817626B1 (fr)
JP (1) JP3260378B2 (fr)
KR (1) KR100286920B1 (fr)
CN (1) CN1072485C (fr)
AP (1) AP646A (fr)
AT (1) ATE172641T1 (fr)
AU (1) AU706161B2 (fr)
CA (1) CA2216623C (fr)
CZ (1) CZ286821B6 (fr)
DE (1) DE69600879T2 (fr)
DK (1) DK0817626T3 (fr)
EA (1) EA000150B1 (fr)
ES (1) ES2128846T3 (fr)
FR (1) FR06C0014I2 (fr)
HU (1) HU224028B1 (fr)
IS (1) IS2048B (fr)
NO (1) NO315968B1 (fr)
NZ (1) NZ304906A (fr)
OA (1) OA10515A (fr)
PL (1) PL183378B1 (fr)
SK (1) SK283883B6 (fr)
TR (1) TR199701048T1 (fr)
UA (1) UA41446C2 (fr)
WO (1) WO1996030010A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283883B6 (sk) * 1995-03-27 2004-04-06 Sanofi-Synthelabo Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
ES2286998T3 (es) * 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (fr) * 2008-07-18 2010-01-21 Zafgen, Inc. Utilisation de fumagillines antiangiogeniques dans le traitement de l'obesite
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (fr) 2011-10-03 2013-04-18 Zafgen Corporation Méthodes de traitement de troubles liés à l'âge
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2011044506A2 (fr) 2009-10-09 2011-04-14 Zafgen Corporation Composés sulfonés et leurs procédés de fabrication et d'utilisation
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
WO2011085198A1 (fr) 2010-01-08 2011-07-14 Zafgen Corporation Inhibiteur de metap-2 pour utilisation dans le traitement d'une hypertrophie bénigne de la prostate (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
WO2012012642A1 (fr) 2010-07-22 2012-01-26 Zafgen Corporation Composés tricycliques et procédés pour les préparer et les utiliser
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
EP2646016B1 (fr) 2010-11-29 2017-05-17 Zafgen, Inc. Traitement de l'obésité à l'aide d'une administration non quotidienne de 6 - 0 - (4 - diméthylaminoéthoxy) cinnamoyl fumagillol
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
CA2872876A1 (fr) 2012-05-08 2013-11-14 Zafgen, Inc. Traitement de l'obesite hypothalamique au moyen d'inhibiteurs de metap2
EP2850079B1 (fr) 2012-05-09 2018-05-02 Zafgen, Inc. Dérivés de fumigillol, procédés pour leurs préparation et leurs utilisation
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CA2890342A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques et procedes de fabrication et d'utilisation associes
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
SK283883B6 (sk) * 1995-03-27 2004-04-06 Sanofi-Synthelabo Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
CA2210600A1 (fr) * 1996-07-17 1998-01-17 Takashi Houkan Inhibiteur des metastases tumorales ou de la recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline

Also Published As

Publication number Publication date
CN1179715A (zh) 1998-04-22
EA199700267A1 (ru) 1998-04-30
AU5278696A (en) 1996-10-16
HU224028B1 (hu) 2005-05-30
NZ304906A (en) 1999-06-29
JPH11506421A (ja) 1999-06-08
CN1072485C (zh) 2001-10-10
EP0817626B1 (fr) 1998-10-28
ES2128846T3 (es) 1999-05-16
HUP9801220A2 (hu) 1999-09-28
KR100286920B1 (ko) 2001-04-16
AP9701092A0 (en) 1997-10-31
MX9707150A (es) 1998-07-31
PL183378B1 (pl) 2002-06-28
HUP9801220A3 (en) 2001-10-29
NO974466L (no) 1997-09-26
IS2048B (is) 2005-09-15
CA2216623C (fr) 2005-05-31
CZ304997A3 (en) 1997-12-17
JP3260378B2 (ja) 2002-02-25
SK283883B6 (sk) 2004-04-06
SK130797A3 (en) 1998-03-04
EP0817626A2 (fr) 1998-01-14
CA2216623A1 (fr) 1996-10-03
NO974466D0 (no) 1997-09-26
EA000150B1 (ru) 1998-10-29
TR199701048T1 (xx) 1998-01-21
FR06C0014I2 (fr) 2006-12-29
WO1996030010A2 (fr) 1996-10-03
ATE172641T1 (de) 1998-11-15
OA10515A (fr) 2002-04-24
FR06C0014I1 (fr) 2006-11-17
DK0817626T3 (da) 1999-07-12
DE69600879D1 (de) 1998-12-03
DE69600879T2 (de) 1999-06-02
KR19980703271A (ko) 1998-10-15
NO315968B1 (no) 2003-11-24
PL322470A1 (en) 1998-02-02
US5900431A (en) 1999-05-04
IS4557A (is) 1997-09-11
AU706161B2 (en) 1999-06-10
UA41446C2 (uk) 2001-09-17
WO1996030010A3 (fr) 1996-11-28
CZ286821B6 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US5348744A (en) Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
EP0190851B1 (fr) Composition anti-inflammatoire
JPH0610141B2 (ja) エイズウイルス性疾患処置剤
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
KR20010072640A (ko) 폐고혈압 치료방법
EP0555302A1 (fr) Procede de traitement des maladies demyelinisantes
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (fr) Utilisation d'isocarbacyclines pour la prevention ou le traitement de maladies d'organes
Stratigos et al. Treatment of gonorrhoea with spectinomycin hydrochloride
JPS6045531A (ja) 抗高脂血症剤
JPH0132804B2 (fr)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH0899883A (ja) 膵炎治療剤